Of note, a study by Zhao et al. (2014) reported that anthracycline neoadjuvant chemotherapy–treated breast cancer patients with high expression of Smac and low expression of survivin had longer disease-free survival and overall survival than those with low expression of Smac and high expression of survivin (Zhao et al., 2014). The gene discussed is BIRC5; the disease is breast carcinoma.